Body Mass Index Can Increase the Risk of Gallbladder Cancer: A Meta-Analysis of 14 Cohort Studies

Hao Liu*
Yong Zhang
Min Ai
Jun Wang
Bo Jin
Zhaowei Teng*
Yansheng Wang
Li Li

* These authors contributed equally to this work

Corresponding Authors:
Li Li, e-mail: Li_Li580923@163.com or Yansheng Wang, e-mail: hydwys2008@163.com

Source of support:
Departmental sources

Background:
This study sought to appraise the association between raised body mass index (BMI) and the risk of gallbladder cancer (GBC) by performing a meta-analysis of 14 cohort studies.

Materials/Methods:
Eligible cohort studies were selected by searching PubMed and EMBASE from their inception to May 26, 2016, and the reference lists of retrieved articles were also consulted. The information was screened by two authors separately. We used a fixed-effects model to calculate the overall pooled risk estimates. A random-effects model was used to identify heterogeneity.

Results:
The meta-analysis incorporated 14 cohort studies. Nine papers were deemed to be of high quality based on the Newcastle-Ottawa Scale (NOS). Compared with normal weight (BMI 18.5–24.9 kg/m²), the overall pooled relative risks (RR) of GBC was 1.45 (95% CI 1.30–1.61) for excess body weight individuals (BMI ≥25 kg/m²); 1.10 (95% CI 1.02–1.18) for overweight persons (BMI 25–29.9 kg/m²) and 1.69(95% CI 1.54–1.86) for obese folks (BMI ≥30 kg/m²). A higher risk of GBC was presented in obese women (women: RR 1.78, 95% CI 1.59–1.99; men: RR 1.50, 95% CI 1.25–1.79). And a positive relationship between overweight and GBC risk was also displayed in female (RR 1.25, 95% CI 1.11–1.40), but not in male (RR 1.01, 95% CI 0.93–1.11). The sensitivity analysis indicated stable results, and no publication bias was observed.

Conclusions:
This meta-analysis of 14 cohort studies demonstrated that raised BMI has a dramatic association with risk of GBC, especially in women. But, no association between overweight and GBC in men was found.

MeSH Keywords:
Body Mass Index • Cohort Studies • Gallbladder Neoplasms • Meta-Analysis

Full-text PDF:
http://www.basic.medscimonit.com/abstract/index/idArt/901651
Background

The World Health Organization (WHO) Cancer Report [1] said that approximately 15 million new cancer cases could be further increased in the next decades. Gallbladder cancer (GBC) is a common disease which has poor prognosis and is highly aggressive [2]. The incidence and mortality rates are the highest cancer rates and the trend is increasing worldwide [3]. Many studies [4–12] have reported multiple factors closely related to GBC, such as gallstones, alcohol consumption, smoking, blood glucose and diabetes mellitus (DM), genetic susceptibility, and obesity. Thus, the etiologies of GBC in its acute stage are of interest.

Body mass index (BMI) is a simple index and an accepted measure used to distinguish excess body weight, including overweight and obesity [13]. A WHO report [14] indicated that global obesity, which is defined as abnormal or excessive fat accumulation, has more than doubled in the past thirty years. Another WHO report [15] indicated that obesity is a well-established risk factor of gallbladder disease. Furthermore, according to WHO, overweight (BMI $\geq 25$ kg/m$^2$) and obesity (BMI $\geq 30$ kg/m$^2$) are recognized as important risk factors for multiple cancer types [16,17]. In our study, we defined excess body weight as BMI $\geq 25$ kg/m$^2$.

Based on the complicated etiology of GBC, obesity plays an important role in biliary tract cancers [18] and the frequency of obesity was high among patients with GBC [19]. In order to further evaluate the relationship between obesity and GBC, we performed this meta-analysis. The study complied with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [20].

Material and Methods

Search strategy and data sources

We searched PubMed and EMBASE (from their inception to May 26, 2016) for cohort studies describing the association between BMI and GBC. To identify any additional studies, the bibliographies of relevant articles were also searched. The search used the following keywords: (1) “Cancer of Gallbladder”, “Gallbladder Cancer”, “Neoplasm, Gallbladder”, “Gallbladder Neoplasm”, “Gallbladder Cancers”, “Bladder Cancers”, “Cancers, Gallbladder”, “Cancers, Bladder”, “Cancer, Gallbladder”, “Cancer, Bladder”, “Bladder Cancers, Gall”, “Bladder Cancer, Gall”, “Neoplasms, Gallbladder”, “Gall Bladder Cancer”, “Cancer of the Gallbladder” [Title/Abstract] OR “Gallbladder Neoplasms” [Mesh]; and (2) “Quetelet Index”, “Index, Quetelet”, “Quetelet Index”, “Quetelet’s Index”, “Index, Body Mass”, “overweight”, “obesity”, “excess body weight” OR “Body Mass Index”[Mesh]; and (3) “cohort study” OR “Cohort Studies”[Mesh].

Study selection

Studies were considered eligible if they met all of the following criteria: (1) a cohort study not a case-control study; (2) it evaluated the association of raised BMI with GBC incidence; (3) the interesting outcome was GBC incidence; (4) the interesting exposure was overweight or obesity defined by BMI; and (5) it provided HRs or RRs and the corresponding 95% CIs or data to calculate them. Extra studies were identified by a hand search of all the references of the retrieved articles.

Data extraction and quality assessment

The two authors (HL and ZWT) independently computed all the retrieved studies based on the aforementioned selection criteria. We also performed a cross-reference search of eligible articles to identify studies which we did not find in the computerized search. The following information from cohort studies were extracted: the name of the first author; publication year; regions of study; study period; sample size; cases size; gender; mean age or age range; follow-up year; BMI categories; assessment of BMI; RR or HR and the 95% CI; and the confounding factors. Together with the co-corresponding authors (LL and YSW), we resolved any disagreements by discussion or consultation. The Newcastle-Ottawa Scale (NOS) [21] was used for methodological quality assessment. The three parameters for quality of a cohort study were consisted with the NOS, namely selection, comparability, and outcome. The maximum NOS score was 9. NOS score $\leq 7.0$ was defined as low quality and NOS score $\geq 7.0$ was high quality.

Statistical analyses

The association between raised BMI and GBC was estimated by computing the pooled RR and its 95% CI, which was calculated from the adjusted RR or HR and 95% CI offered in the studies. In this meta-analysis, HRs was deemed equivalent to relative risks (RRs) [22]. The Q test and the I$^2$ test [23] were used to assess the studies heterogeneity. The D-L random effects model [24] was used as the pooling method when significant heterogeneity existed and the M-H fixed effect model [25] was used when no heterogeneity was observed. Subgroup analyses by gender, geographic location, and follow-up time ($\geq 10$ years and $<10$ years) were performed in order to further explore the origin of heterogeneity. Additionally, Begg funnel plots and Egger regression test [26] were done to test potential publication bias. The data analyses were performed using Stata version 13.1 (StataCorp LP, College Station, TX, USA).
META-ANALYSIS

Body mass index can increase the risk of gallbladder cancer.

Liu H. et al.

© Med Sci Monit Basic Res, 2016; 22: 146-155

Results

Literature search and study characteristics

As shown in Figure 1, a total of 218 articles (90 from PubMed and 128 from EMBASE) were retrieved. Among these articles, 204 articles were excluded after screening the titles and abstracts, eliminating repetitions, and reviewing the full paper. Finally, we retained 14 cohort studies in our analysis. Six [10,27–31] of the 14 cohort studies were from Europe, five [32–36] were from Asia and three [37–39] were from America. The main information and NOS scores of the 14 studies are summarized in Table 1. Nine of the 14 articles were high-quality studies (scores ≥7.0).

Main analysis

The meta-analysis, which included 10,530,142 individuals, found a positive association between excess body weight and GBC risk (RR 1.45, 95% CI 1.30–1.61) compared with normal weight (Figure 2). After combining the data, we also found a promising association between overweight and GBC risk (RR 1.10, 95% CI 1.02–1.18) compared with normal weight (Figure 3). In addition, we found a dramatic association between obesity and GBC risk (RR 1.69, 95% CI 1.54–1.86) compared with normal weight (Figure 4). No heterogeneities were observed.

Subgroup meta-analysis

Depending on the subgroup analysis of gender, a promising connection between BMI and GBC risk was observed, especially in women. Higher risks for GBC were present in women compared to men who had BMI of excess body weight and obesity. No relationship was found in overweight men (RR 1.01, 95% CI 0.93–1.11). When BMI ≥25 kg/m², statistical heterogeneity was observed in women (p=0.002; I²=59.3). A positive relationship between excess body weight and obesity and GBC risk were revealed in the subgroup analysis of study region. No statistical heterogeneity was observed in the European group. Moreover, among each stratum of BMI, the risk of GBC in the Asia group was lower than the other three groups. Additionally, we also observed statistical heterogeneity in American overweight and excess body weight groups. Furthermore, no association was observed between overweight and GBC risk in the follow-up ≥10 year group (RR 1.05, 95% CI 0.97–1.15) (Table 2).

Sensitivity analysis

To appraise the study’s robustness, a sensitivity analysis was performed by excluding one study per iteration and recounting the pooled results of the primary analysis. The overall combined result was stable (Figure 5).

Publication bias

Among the studies, no evidence of publication bias was appeared by the Begg test and Egger linear regression test [Begg, p>|z|=0.125; Egger, p=0.051, 95% CI: −0.065–2.519] (Figures 6, 7).

Discussion

The primary results of this study demonstrated that excess body weight, overweight, or obesity were associated with an increase in GBC risk. In this meta-analysis, we found that the risk of GBC were 1.45 times, 1.10 times, and 1.69 times than the risk of GBC for an increment of 5 kg/m², overweight (BMI 25–29.9 kg/m²) and obesity (BMI ≥30 kg/m²) groups, respectively. Among each stratum of BMI, the risk of GBC in men was lower than women, a finding that was consistent with previous studies. Our sensitivity analysis suggested that the combined results were stable and robust. No publication bias was observed in our study.

The etiology of gallbladder carcinoma involves an intricate interaction of metabolic alterations [40]. Numerous of studies [4,5,41] have confirmed that gallstone are the main cause of GBC. We found that obesity was not only strongly associated with gallstones [42] but also had an increased frequency of gallstones [43]. Another study [44] found that obese people had supersaturated gallbladder bile accounting for the inclination to cholesterol cholelithiasis. In addition, diabetes has been shown to be a risk factor for gallstones [45] in general, and in people with abdominal obesity [46]. A Danish study [47] found a positive association between elevated glucose levels and gallbladder carcinoma. When individuals with gallstone diseases or unknown status were excluded in an analyses on GBC, one study [46] found that the risk of GBC was 1.50 times (1.01–2.22) than the risk of GBC for an increment of 5 kg/m² in

---

Figure 1. Flow chart illustrating the literature search for cohort studies on BMI in relation to GBC. BMI – means body mass index; GBC – means gallbladder cancer.

Table 1: Characteristics and NOS scores of the 14 cohort studies

- PubMed: N=90
- EMBASE: N=128
- 218 identified articles from the databases
- 204 studies were excluded based on removing duplicates, screening title and abstract with inclusion criteria and no relevant content
- 14 cohort articles were finally included in our meta-analysis

---

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

Indexed in: [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]
| Author, year, country (study period) | Sample | Age: Mean or range | Follow-up years | BMI ascertainment | BMI categories (kg/m²) | RR and 95% CI | Adjustments | NOS |
|-----------------------------------|--------|------------------|----------------|------------------|-----------------------|--------------|-------------|-----|
| Ikuko Kato, 1992, Hawaii (1965–1968) | 7,831 m | Born from 1900 to 1919 | ≥22 | Measured | <21.65 21.65–23.19 23.80–25.80 ≥25.80 | NA 1.0 1.1 (0.9–1.5) 1.4 (1.1–1.9) 1.8 (1.4–2.3) | Occupation, education, smoking, dietary, alcohol, age, physical activity | 6 |
| Moller, 1994, Denmark (1977–1987) | 43,965 | 50 m 60 f | 5 | Discharge diagnosis | Non-obese Obese | 1.30 (0.8–1.8) 0.50 (0.1–1.8) 1.40 (0.9–2.1) | Age | 6 |
| Wolk, 2001, Sweden (1965–1993) | 28,129 | 46.1 | 10.3 | Discharge diagnosis | Non-obese Obese | 1.60 (1.1–2.3) 0.90 (0.1–3.4) 1.70 (1.1–2.5) | Age, calendar year | 7 |
| Calle, 2003, USA (1982–1998) | 900,053 | 57 | 16 | Self-reported | 18.5–24.9 25.0–29.9 30.0–34.9 ≥35 | NA 1.00 (reference) 1.34 (0.97–1.84) 1.76 (1.06–2.94) NA | Age, race, marital status, smoking, aspirin, alcohol, estrogen therapy | 8 |
| Samanic, 2004, USA (1969–1996) | 4,500,700 m: 832,214 W: 3,668,486 | 52.18 W 47.63 B | 1–27 | Discharge diagnosis | Non-obese Obese | 1.62 (1.09–2.41) 0.93 (0.23–3.86) W: 1.70 (1.13–2.57)B | Age, calendar year | 6 |
| Anders, England, 2005, Norway (1963–2001) | 2,001,511 | 44(20–74) | 23 | Measured | <18.5 18.5–24.9 25.0–29.9 ≥30.0 | NA 0.31 (0.04–2.24) 1.00 (referent) 1.00 (referent) | Age, birth | 7 |
| Kuriyama, 2005, Japan (1984–1992) | 27,539 | ≥40 | 9 | Self-reported | <18.5 18.5–24.9 25.0–29.9 ≥30.0 | NA 1.00 (reference) 0.46 (0.05–3.93) NA | Age, smoking, health insurance, alcohol | 7 |
| Sang Woo Oh, 2005, Korea (1992–2001) | 781,283 m | ≥20 | 10 | Measured | <18.5 18.5–22.9 23.0–24.9 25.0–26.9 27.0–29.9 ≥30.0 | NA 2.44 (1.12–5.34) 1.00 (reference) 1.5 (1.10–2.20) 1.1 (0.74–1.80) 1.2 (0.70–2.24) NA | Age, smoking, alcohol, exercise, region | 7 |
| Samanic, 2006, Sweden (1971–1999) | 362,552 m | 18-67 | 28 | Measured | <18.5 18.5–29.9 ≥30.0 | NA 0.93 (0.62–1.39) 1.40 (0.73–2.70) | Age, smoking | 8 |
Another analysis [17] found that the risk of GBC in individuals with gallstones was 1.31 times (1.12–1.52). Rapp et al. [12] reported that elevated BMI was positively correlated with blood glucose. Thus, we can affirm that obesity could increase the prevalence of GBC by promoting formation of gallstones and elevating blood glucose level. Some studies [48–50] have shown that retinol binding protein 4 (RBP4) is closely associated with insulin resistance and obesity. Elevated RBP4 has been shown to increase the incidence rate of gallstone disease [51]. Wang et al. [52] reported that bile RBP4 was correlated with BMI positively. Hence, we can suppose that increased BMI may play a role in the course of gallstone formation so as to influence the morbidity of GBC by elevating RBP4. These aforementioned interconnected pathways may suggest pathophysiological mechanism of the obesity-cancer link.

However, one study [53] showed that estrogen was the main factor for the difference between males and females in terms of gallbladder stone formation. Another study [54] revealed that exogenous estrogens affected physiological markers facilitating gallstones formation. In addition, estrogens play a role in cholesterol secretion increasing and bile salt secretion diminishing [2]. Female sex hormones influence hepatic bile secretion and gallbladder function adversely [55] and oral hormonal replacement therapy could increase the risk of GBC [2], which have been shown to play an important role in the carcinogenesis process of this organ. These findings may partially explain the reason why the connection between raised BMI and GBC was stronger in women than in men.

### Table 1 continued. Characteristics of 14 cohort studies.

| Author, year, country (study period) | Sample | Age: Mean or range | Follow-up years | BMI ascertainment | BMI categories (kg/m²) | RR and 95% CI | Adjustments | NOS |
|-------------------------------------|--------|--------------------|----------------|------------------|-----------------------|---------------|-------------|-----|
| Ishiguro, 2008, Japan (1994–2004)   | 101,868| 40–69              | 10.9           | Self-reported    | ≤22.9 23.0–24.9 25.0–26.9 ≥27.0 | NA 1.00 (reference) 0.74 (0.28–1.92) 1.26 (0.48–3.33) 1.39 (0.45–4.34) | Age, gender, study area, diabetes, smoking, alcohol | 6 |
| Sun Ha Jee, 2008, Korea (1992–2006) | 1,213,829| 45.0 m 49.4 f    | 10.8           | Measured        | 25.0–29.9 ≥30 | 1.00 (0.89–1.12) 1.54 (1.17–2.03) | Age, smoking, alcohol, physical activity | 8 |
| Yun-Mi Song, 2008, Korea (1994–2003)| 170,481| 40–64              | 8.75           | Measured        | <18.5 18.5–20.9 21.0–22.9 23.0–24.9 25.0–26.9 27.0–29.9 ≥30 | NA NA 1.91 (0.78–4.68) 1.35 (0.74–2.47) 1.00 (reference) 1.06 (0.62–1.80) 1.30 (0.76–2.22) 1.86 (1.09–3.18) 2.10 (0.97–4.51) | Age, height, smoking, alcohol, exercise, pay level | 7 |
| Kari Hemminki, 2011, Sweden (1964–2006) | 30,020 | NA 11.2 | Discharge diagnosis | Non-obese | 1.73 (1.16–2.57) | NA 1.55 (0.93–2.43) | Age, sex, region, economic status | 7 |
| Schlesinger, 2013, Europe (1992–2000) | 363,426| 25–70              | 8.5            | Discharge diagnosis | Non-obese | 2.71 (1.17–6.31) | Weight, height, waist circumference, alcohol, smoking, education, diet, lifestyle, medical history, Blood samples | 6 |

BMI – means body mass index (kg/m²); RR – represents the relative risk; CI – represents the confidence interval; m – means men; f – means female; B – means black; W – means white; NA – represents data not applicable; NOS – means the Newcastle-Ottawa Scale.
Figure 2. Forest plot of risk of GBC associated with excess body weight (BMI $\geq 25$ Kg/m$^2$) in general population.

| Study ID                  | ES (95% CI) | % weight |
|---------------------------|-------------|----------|
| Ikuko Kato, 1992, Hawaii   | 1.80 (1.40, 2.30) | 15.61    |
| Moller, 1994, Denmark      | 1.30 (0.80, 1.80)  | 5.85     |
| Wolk, 2001, Sweden         | 1.60 (1.10, 2.10)  | 7.07     |
| Calle, 2003, USA           | 1.51 (1.11, 2.07)  | 9.90     |
| Samanic, 2004, USA         | 1.62 (1.09, 2.41)  | 6.31     |
| Anders Engeland, 2005, Norway | 1.35 (1.01, 1.79) | 11.75    |
| Kuriyama, 2005, Japan      | 2.32 (1.02, 5.30)  | 1.42     |
| Sang Woo Oh, 2005, Korea   | 1.19 (0.83, 5.30)  | 7.61     |
| Samanic, 2006, Sweden      | 1.04 (0.74, 1.47)  | 8.16     |
| Ishiguro, 2008, Japan      | 0.92 (0.61, 1.41)  | 5.48     |
| Sun Ha Jee, 2008, Korea    | 1.22 (0.80, 1.86)  | 5.40     |
| Yun-Mi Song, 2008, Korea   | 1.65 (1.17, 2.32)  | 8.21     |
| Kari Hemminki, 2011, Sweden| 1.73 (1.16, 2.57)  | 6.08     |
| Schlesinger, 2013, Europe  | 2.71 (1.17, 6.31)  | 1.35     |
| Overall (I-squared=30.5%, p=0.1333) | 1.45 (1.31, 1.59) | 100.00   |

Figure 3. Forest plot of risk of GBC associated with overweight (25–29.9 Kg/m$^2$) in general population.

| Study ID                  | ES (95% CI) | % weight |
|---------------------------|-------------|----------|
| Calle, 2003, USA, men     | 1.34 (0.97, 1.84) | 4.75     |
| Anders Engeland, 2005, Norway, men | 1.00 (0.84, 1.17) | 17.72    |
| Kuriyama, 2005, Japan, men | 0.46 (0.05, 3.93) | 0.10     |
| Sang Woo Oh, 2005, Korea, men | 1.19 (0.83, 1.69) | 3.85     |
| Samanic, 2006, Sweden, men | 0.93 (0.62, 1.39) | 2.98     |
| Ishiguro, 2008, Japan, men | 1.26 (0.48, 3.33) | 0.52     |
| Sun Ha Jee, 2008, Korea, men | 0.97 (0.86, 1.10) | 32.11    |
| Calle, 2003, USA, women   | 1.12 (0.86, 1.47) | 6.77     |
| Anders Engeland, 2005, Norway, women | 1.27 (1.10, 1.47) | 23.14    |
| Kuriyama, 2005, Japan, women | 1.77 (0.44, 7.08) | 0.25     |
| Ishiguro, 2008, Japan, women | 0.62 (0.29, 1.34) | 0.83     |
| Sun Ha Jee, 2008, Korea, women | 1.27 (1.02, 2.12) | 3.63     |
| Yun-Mi Song, 2008, Korea, women | 1.10 (1.06, 2.27) | 3.35     |
| Overall (I-squared=35.2%, p=0.101) | 1.10 (1.02, 1.18) | 100.00   |

Figure 4. Forest plot of risk of GBC associated with obesity ($\geq 30$ Kg/m$^2$) in general population.

| Study ID                  | ES (95% CI) | % weight |
|---------------------------|-------------|----------|
| Moller, 1994, Denmark, men | 0.50 (0.10, 1.80) | 0.45     |
| Wolk, 2001, Sweden, men   | 0.90 (0.10, 3.40) | 0.30     |
| Calle, 2003, USA, men     | 1.76 (1.06, 2.94) | 3.60     |
| Samanic, 2006, Sweden, men | 1.62 (1.09, 2.41) | 5.96     |
| Anders Engeland, 2005, Norway, men | 1.38 (1.01, 1.89) | 9.55     |
| Samanic, 2006, Sweden, men | 1.40 (0.73, 2.70) | 2.19     |
| Ishiguro, 2008, Japan, men | 1.39 (0.45, 4.34) | 0.73     |
| Sun Ha Jee, 2008, Korea, men | 1.65 (1.13, 2.94) | 6.05     |
| Moller, 1994, Denmark, women | 1.40 (0.90, 2.10) | 5.22     |
| Wolk, 2001, Sweden, women | 1.70 (1.10, 2.50) | 5.57     |
| Calle, 2003, USA, men     | 2.13 (1.56, 2.90) | 9.76     |
| Anders Engeland, 2005, Norway, women | 1.88 (1.60, 2.21) | 35.96    |
| Kuriyama, 2005, Japan, women | 4.45 (1.39, 14.23) | 0.69     |
| Ishiguro, 2008, Japan, women | 0.94 (0.48, 1.88) | 2.01     |
| Sun Ha Jee, 2008, Korea, women | 1.44 (0.98, 2.12) | 6.30     |
| Yun-Mi Song, 2008, Korea, women | 2.10 (0.97, 4.51) | 1.59     |
| Kari Hemminki, 2011, Sweden, women | 1.55 (0.93, 2.43) | 4.07     |
| Overall (I-squared=3.0%, p=0.418) | 1.69 (1.54, 1.86) | 100.00   |
Table 2. Subgroup analyses of the association between BMI and GBC risk.

|                     | Overweight (25–29.9 Kg/m^2) | Obesity (³30 Kg/m^2) | Excess body weight (³25 Kg/m^2) |
|---------------------|----------------------------|----------------------|---------------------------------|
| Studies             | RR (95%CI)                  | P (I^2)              | RR (95%CI)                      | P (I^2) |
| Sex                 |                            |                      |                                 |
| Men                 |                            |                      |                                 |
| 6                   | 1.01 (0.93, 1.11)           | 0.532 (0.0)          | 9                               | 1.50 (1.25, 1.79) | 0.822 (0.0) |
| Women               |                            |                      |                                 |
| 6                   | 1.25 (1.11, 1.40)           | 0.362 (8.5)          | 9                               | 1.78 (1.59, 1.99) | 0.237 (23.2) |
| Region              |                            |                      |                                 |
| Asia                |                            |                      |                                 |
| 5                   | 1.04 (0.94, 1.16)           | 0.193 (34.3)         | 4                               | 1.55 (1.23, 1.96) | 0.136 (45.9) |
| Europe              |                            |                      |                                 |
| 2                   | 1.07 (0.88, 1.32)           | 0.415 (0.0)          | 5                               | 1.56 (1.31, 1.87) | 0.861 (0.0) |
| America             |                            |                      |                                 |
| 2                   | 1.47 (0.99, 2.16)           | 0.016 (82.8)         | 2                               | 1.89 (1.51, 2.35) | 0.365 (0.0) |
| Non-Asia            |                            |                      |                                 |
| 4                   | 1.14 (0.96, 1.37)           | 0.157 (50.1)         | 7                               | 1.68 (1.46, 1.93) | 0.185 (43.0) |
| Follow-up time      |                            |                      |                                 |
| <10                 |                            |                      |                                 |
| 2                   | 1.52 (1.06, 2.19)           | 0.677 (0.0)          | 3                               | 1.59 (1.13, 2.24) | 0.106 (55.1) |
| ≥10                 |                            |                      |                                 |
| 6                   | 1.05 (0.97, 1.15)           | 0.490 (0.0)          | 7                               | 1.70 (1.49, 1.93) | 0.449 (0.0) |

BMI – represents the body mass index; GBC – represents the gallbladder cancer; RR – represents the relative risk; CI – represents the confidence interval; the values of P and I^2 represent the heterogeneity.

Figure 5. Sensitivity analysis of the association between BMI (³25 Kg/m^2) and GBC.
A meta-analysis [56] found that BMI for persons from East Asian countries was 1.9–3.2 kg/m² lower than for Caucasians, when they were at the same percentage of body fat. Another study [57] found that compared with Asian populations, Western white populations have a lower percentage of body fat at a particular BMI level. For the aforementioned evidence, Asian populations may have a higher risk of GBC than Caucasians. But in our study, the subgroup meta-analysis found that the risk of GBC in the Asia group was lower than the other three groups within each stratum of BMI. It is possible that race or lifestyle is a principal factor. One research study [58] concluded that a Western diet elevates body adiposity without changing body weight. BMI associating with cancer risk was defined by a Western cut-off point [35]. Hence, what we need is the establishment of different cut-off points for Asian populations or identical cut-off points for the globe population.

There were several strengths in our meta-analysis. Observational studies cannot prove causality [59]. All of the included studies were cohort design with no epidemiological observational studies, which are considered a higher level of study design. A majority of the cohorts comprised at least one RR and 95% CI, allowing for subgroup analysis. Fourteen studies followed the participants for a long time (e.g., 10 years). All the included studies estimated multiple confounders. Of the studies that had large sample sizes, nine studies were judged to be high quality. Additionally, though several studies with high I² values (Table 2) were presented in certain subgroup analyses, we did not find heterogeneity in the three main analyses presented. However, in the subgroup analysis of study regions, studies conducted in America made principal contributions to heterogeneity. The number of articles (only three) may be an important reason for the heterogeneity. Yet, no heterogeneity was observed after we put the European group and American group into one group called non-Asian group. In addition, gender and follow-up year also introduced heterogeneity to some extent in the subgroup analysis. When more data is available, we will evaluate these factors again, in a future study.

Regardless of the advantages of this study, the meta-analysis also had limitations. First, notwithstanding that we searched all cohort studies for the association between BMI and GBC risk; all eligible studies were restricted to English language publications. This linguistic barrier excluded some non-English language studies. We also missed some studies published in a book or a journal that was not available through the internet databases. Additionally, journals may reject studies with non-significant results, or studies showing an absence of effect may not be submitted by investigators. Fortunately, no publication bias was found in our study, although we could not rule out publication bias completely. Second, a few studies did not present clear or entire data, making data analysis difficult. For this reason, in the sub-analysis, the sum of some of the groups’ data were not equal to the total numbers included in the literature. When we could not get original data from the authors by email or other means, we combined data. Moreover, some studies only described the relationship between BMI and men or women and did not describe the relationship among the general population. In these cases, we dealt with the data only in subgroup analysis depending on gender. In the gender sub-group analysis, significant heterogeneity was found in data for women whose BMI ≥25 kg/m²; unfortunately, we did not find the reason for this heterogeneity by searching the databases. Furthermore, the class of BMI of other studies did not always follow the WHO criterion. In order to resolve this problem, we chose the class of BMI closest to the WHO criterion. For example in one study [37], the authors divided BMI (kg/m²) into <21.65, 21.65–23.19, 23.80–25.80, and >25.80, and we then classified BMI >25.80 kg/m² as excess body weight group. Another study [33] divided BMI (kg/m²) classes into 25.0–6.9, 27.0–29.9, and ≥30.0. Similarly, we combined 25.0–26.9 and 27.0–29.9 into one group. No heterogeneity was observed. Third, although nine of the fourteen studies were considered high quality, the NOS score of five articles were less than 7. In other word, nearly one third of the study reports supplied vague data, which would overestimate the
pooled effect. Fourth, we did not appraise all the adjustments for confounders. The subgroup analysis only used gender, region, and follow-up year without other confounding factors. One meta-analysis [60] noted that smoking and alcohol consumption were also strongly associated with GBC risk in overweight people. Considering the difference and uncontrollability of lifestyles among people, we assumed that all confounders were equal, and our results were consistent with this assumption. Fifth, although BMI is the authoritative measure for normal weight assessment, there are still other tools for weight assessment used in judging abdominal adiposity that may be more sensitive in forecasting the risk of cancer, namely waist-to-hip ratio and waist circumference. Adipose tissue is known to play a positive role in tumor microenvironment [61]. However, BMI cannot make the distinction between fat mass and muscle mass. Finally, because of the small number of eligible articles, our study was not the most comprehensive. Thus, more comprehensive and higher quality analyses are still required in the future when more practicable data are published.

**Conclusions**

In summary, the cohort studies meta-analysis indicated that raised BMI played an important role in the risk of GBC. Further studies that meet strict criteria on this subject are needed in order to provide more convincing evidence and to reinforce the association between BMI and GBC risk.

**Conflicts of interest**

All authors declared no conflicts of interest.

**References:**

1. Global cancer rates could increase by 50% to 1.5 million by 2020. WHO Report, http://www.who.int/mediacentre/news/releases/2003/pr27/en/

2. Gabbi C, Kim HJ, Barros R et al: Estrogen-dependent gallbladder carcinogenesis in LKRbeta+/– female mice. Proc Natl Acad Sci USA, 2010; 107(33): 14763–68

3. Braccon C, Patel T: Cholangiocarcinoma: new insights into disease pathogenesis and biology. In: In: Clin North Am, 2010; 24(4): 871–84, vii

4. Misra S, Chaturvedi A, Misra NC, Sharma ID: Carcinoma of the gallbladder. Lancet Oncol, 2003; 4: 167–76

5. Hsing AW, Bai Y, Andreotti G et al: Family history of gallstones and the risk of biliary tract cancer and gallstones: A population-based study in Shanghai, China. Int J Cancer, 2007; 121: 832–8

6. Hou L, Xu L, Gao YT et al: CYPI7 MsplA polymorphism and risk of biliary tract cancers and gallstones: A population-based study in Shanghai, China. Int J Cancer, 2006; 118: 2847–53

7. Moerman CJ, Bueno de Mesquita HB, Runia S: Smoking, alcohol consumption and the risk of cancer of the biliary tract; A population-based case-control study in The Netherlands. Eur J Cancer Prev, 1994; 3: 427–36

8. Ji J, Hemminki K: Variation in the risk for liver and gallbladder cancers in socioeconomically and occupational groups in Sweden with etiological implications. Int Arch Occup Environ Health, 2005; 78: 641–49

9. Jamal MM, Yoon EJ, Vega KJ: Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. J Clin Gastroenterol, 2009; 15: 5274–78

10. Schlesinger S, Aleksandrova K, Pischon T et al: Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepato-cellular carcinoma in a European cohort. Ann Oncol, 2013; 24(9): 2449–55

11. Stocks T, Rapp K, Bjørge T et al: Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): Analysis of six prospective cohorts. PLoS Med, 2009; 6(12): e1000201

12. Rapp KJ, Schroeder J, Klenk J et al: Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia, 2006; 49(5): 945–52

13. 10 facts on obesity. WHO Report, http://www.who.int/mediacentre/factsheets/obesity/facts/en/

14. Obesity and overweight. Fact sheet N°311. WHO Report, 2015, http://www.who.int/mediacentre/factsheets/fs311/en/

15. Part 12: 2009 Core Module Rationale 2009 Manual for Conducting the Global School-based Student Health Survey. WHO Report, 2009; 12–16

16. Song X, Pukkala E, Dyba T et al: Body mass index and cancer incidence: The FINRISK study. Eur J Epidemiol, 2014; 29(7): 477–87

17. Bhaskaran K, Douglas I, Forbes H et al: Body-mass-index and risk of 22 specific cancers: A population-based cohort study of 5.24 million UK adults. Lancet, 2014; 384(9945): 755–65

18. Park M, Song DY, Je Y, Lee JE: Body mass index and biliary tract disease: A systematic review and meta-analysis of prospective studies. Prev Med, 2012; 54(4): 15: 63–22

19. Kaaks R, Kuhn T: Epidemiology: Obesity and cancer – the evidence is fattening up. Nat Rev Endocrinol, 2014; 10(11): 644–45

20. Stroup DF, Berlin JA, Morton SC: Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA, 2000; 283: 2008–12

21. Wells GA, Shea B, O’Connell D et al: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Ottawa Hospital Research Institute: Ottawa, ON, 2013

22. Greenland, S: Quantitative methods in the review of epidemiologic literature. Epidemiol Rev, 1987; 9: 1–30

23. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ, 2003; 327(7414): 557–60

24. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med, 2002; 21(15): 1539–58

25. Leonard T, Duffy JC: A Bayesian fixed effects analysis of the Mantel-Haenszel model applied to meta-analysis. Stat Med, 2002; 21(16): 2295–312

26. Harbord RM, Egger M, Sterne JA: A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med, 2006; 25(20): 3443–57

27. Moller H, Mellemgaard A, Lindvig K, Olsen JH: Obesity and cancer risk: A Danish record-linkage study. Eur J Cancer, 1994; 30a(3): 344–50

28. Wolk A, Gridley G, Svensson M et al: A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control, 2001; 12(1): 13–21

29. Engeland A, Tretli S, Austad G, Bjørge T: Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes Control, 2005; 16(8): 987–96

30. Samanic C, Chow WH, Gridley G et al: Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control, 2006; 17(7): 901–9

31. Hemminki K, Li X, Sundquist J, Sundquist K: Obesity and familial obesity and risk of cancer. Eur J Cancer Prev, 2011; 20(5): 438–43

32. Kuryama S, Tsutabata H, Hozawa A et al: Obesity and risk of cancer in Japan. Int J Cancer, 2005; 113(1): 148–57

33. Oh SW, Yoon YS, Shin SA: Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol, 2005; 23(21): 4742–54

34. Ishiguro S, Inoue M, Kurahashi N et al: Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (PHC study), with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Causes Control, 2008; 19(1): 33–41

35. Jee SH, Yun JE, Park EJ et al: Body mass index and cancer risk in Korean men and women. Int J Cancer, 2008; 123(8): 1892–96
36. Song YM, Sung J, Ha M: Obesity and risk of cancer in postmenopausal Korean women. J Clin Oncol, 2008; 26(20): 3395–402
37. Kato I, Nomura A, Stemmermann GN, Chyou PH: Prospective study of clinical gallbladder disease and its association with obesity, physical activity, and other factors. Dig Dis Sci, 1992; 37(5): 784–90
38. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MI: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 2003; 348(17): 1625–38
39. Samanic C, Gridley G, Chow WH et al: Obesity and cancer risk among white and black United States veterans. Cancer Causes Control, 2004; 15(1): 35–43
40. Misra S, Chaturvedi A, Misra NC, Sharma ID: Carcinoma of the gallbladder. Lancet Oncol, 2003; 4(3): 167–76
41. Xu Q, Tao LY, Wu Q et al: Prevalences of and risk factors for biliary stones and gallbladder polyps in a large Chinese population. HPB (Oxford), 2012; 14(6): 373–81
42. Ben-Menachem T: Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol, 2007; 19(8): 615–17
43. Lowenfels AB, Maisonneuve P, Boyle P, Zatonski WA et al: Epidemiology of gallbladder cancer. Hepatogastroenterology, 1999; 46(27): 1529–32
44. Bennion LJ, Grundy SM: Effects of obesity and caloric intake on biliary lipid metabolism in man. J Clin Invest, 1975; 56(4): 996–1011
45. Portincasa P, Di Ciaula A, De Bari O et al: Management of gallstones and its related complications. Expert Rev Gastroenterol Hepatol, 2016; 10(1): 93–112
46. Schlesinger S, Aleksandrova K, Pischon T et al: Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer, 2013; 132(3): 645–57
47. Wideroff L, Gridley G, Mellemkjaer L et al: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst, 1997; 89(18): 1360–65
48. Yang Q, Graham TE, Mody N et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 2005; 436(7049): 356–62
49. Tajtákóvá M, Semanová Z, Ivancová G et al: [Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin]. Vnitr Lek, 2007; 53(9): 960–63 [in Slovak]
50. Li L1, Wang C, Bao Y et al: Serum retinol-binding protein 4 is associated with insulin secretion in Chinese people with normal glucose tolerance. J Diabetes, 2009; 1(2): 125–30
51. Han T, Zhang D, Fu Z et al: Retinol-binding protein 4 as a risk factor for cholesterol gallstone formation. Mol Cell Biochem, 2013; 377(1–2): 219–27
52. Wang W, Li N: [Correlation of retinol binding protein 4 with metabolic indexes of glucose and lipid, bile cholesterol saturation index]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2015; 40(6): 657–65 [in Chinese]
53. Kim SS, Lee JG, Kim DW et al: Insulin resistance as a risk factor for gallbladder stone formation in Korean postmenopausal women. Korean J Intern Med, 2011; 26(3): 285–93
54. Uhler ML, Marks JW, Voigt BI, Ludd HL et al: Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women. J Clin Endocrinol Metab, 1998; 83(2): 410–14
55. Cirillo DJ, Wallace RB, Rodabough RJ et al: Effect of estrogen therapy on gallbladder disease. JAMA, 2005; 293(3): 330–39
56. Deurenberg P, Yap M, van Staveren WA: Body mass index and percent body fat: A meta-analysis among different ethnic groups. Int J Obes Relat Metab Disord, 1998; 22(12): 1164–71
57. WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet, 2004; 363(9403): 157–63
58. Heinonen I, Rinne P, Ruohonen ST et al: The effects of equal caloric high fat and western diet on metabolic syndrome, oxidative stress and vascular endothelial function in mice. Acta Physiol (Oxf), 2014; 211(3): 515–27
59. Xu T, Zhang YH: Association of psoriasis with stroke and myocardial infarction: Meta-analysis of cohort studies. Br J Dermatol, 2012; 167(6): 1345–50
60. Tan W, Guo M, Liu N et al: Body mass index and risk of gallbladder cancer: Systematic review and meta-analysis of observational studies. Nutrients, 2015; 7: 8321–34
61. Moriuchi H, Yamaguchi J, Hayashi H et al: Cancer cell interaction with adipose tissue: Correlation with the finding of spiculation at mammography. Radiology, 2016; 279(1): 56–64